144 related articles for article (PubMed ID: 8344744)
1. Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3.
van Ravenswaay Claasen HH; van de Griend RJ; Mezzanzanica D; Bolhuis RL; Warnaar SO; Fleuren GJ
Int J Cancer; 1993 Aug; 55(1):128-36. PubMed ID: 8344744
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
3. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones.
Ferrini S; Prigione I; Miotti S; Ciccone E; Cantoni C; Chen Q; Colnaghi MI; Moretta L
Int J Cancer; 1991 May; 48(2):227-33. PubMed ID: 1826900
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen.
van Dijk J; Warnaar SO; van Eendenburg JD; Thienpont M; Braakman E; Boot JH; Fleuren GJ; Bolhuis RL
Int J Cancer; 1989 Feb; 43(2):344-9. PubMed ID: 2521843
[TBL] [Abstract][Full Text] [Related]
5. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
6. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
7. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components.
Mezzanzanica D; Canevari S; Ménard S; Pupa SM; Tagliabue E; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Apr; 41(4):609-15. PubMed ID: 3258590
[TBL] [Abstract][Full Text] [Related]
8. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.
Jacobs N; Mazzoni A; Mezzanzanica D; Negri DR; Valota O; Colnaghi MI; Moutschen MP; Boniver J; Canevari S
Cancer Immunol Immunother; 1997 Jul; 44(5):257-64. PubMed ID: 9247560
[TBL] [Abstract][Full Text] [Related]
9. Re-targeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies.
Ferrini S; Prigione I; Mammoliti S; Colnaghi MI; Ménard S; Moretta A; Moretta L
Int J Cancer; 1989 Aug; 44(2):245-50. PubMed ID: 2527207
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
11. The use of hybrid hybridomas to target human cytotoxic T lymphocytes.
Lanzavecchia A; Scheidegger D
Eur J Immunol; 1987 Jan; 17(1):105-11. PubMed ID: 3102250
[TBL] [Abstract][Full Text] [Related]
12. Production of bi-specific monoclonal antibodies in a hollow-fibre bioreactor.
Gorter A; van de Griend RJ; van Eendenburg JD; Haasnoot WH; Fleuren GJ
J Immunol Methods; 1993 May; 161(2):145-50. PubMed ID: 8505544
[TBL] [Abstract][Full Text] [Related]
13. Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells.
Canevari S; Ménard S; Mezzanzanica D; Miotti S; Pupa SM; Lanzavecchia A; Colnaghi MI
Int J Cancer Suppl; 1988; 2():18-21. PubMed ID: 3258291
[TBL] [Abstract][Full Text] [Related]
14. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.
Möller SA; Reisfeld RA
Cancer Immunol Immunother; 1991; 33(4):210-6. PubMed ID: 1647871
[TBL] [Abstract][Full Text] [Related]
15. A dual-chamber system for screening cytotoxic effects of hybridoma-produced antibodies.
Long TT; Kalantarov G; Chudner A; Trakht I
Monoclon Antib Immunodiagn Immunother; 2013 Aug; 32(4):246-54. PubMed ID: 23909417
[TBL] [Abstract][Full Text] [Related]
16. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.
Mezzanzanica D; Canevari S; Colnaghi MI
Int J Clin Lab Res; 1991; 21(2):159-64. PubMed ID: 1815760
[TBL] [Abstract][Full Text] [Related]
17. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
18. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH
Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619
[TBL] [Abstract][Full Text] [Related]
19. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
[TBL] [Abstract][Full Text] [Related]
20. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
Pupa SM; Canevari S; Fontanelli R; Ménard S; Mezzanzanica D; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Sep; 42(3):455-9. PubMed ID: 2971021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
